Drug intelligence / Profile preview

bifidobacterium infantis CURE 21

Development stage: Unknown
Lead developer: Beijing Incuris Biological Products Research Institute
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium infantis CURE 21 is a live biotherapeutic product (LBP) consisting of a specific strain of *Bifidobacterium longum* subsp. *infantis*. Developed by Beijing Incuris Biological Products Research Institute, it is formulated as the Tongli Enteric-Coated Capsule. The drug is primarily targeted at treating gastrointestinal conditions such as functional constipation and irritable bowel syndrome (IBS). Its mechanism involves the modulation of the intestinal microbiota, improvement of gut barrier function, and regulation of intestinal motility. It has reached Phase 3 clinical trials in China for the treatment of constipation, specifically addressing patterns characterized by heat accumulation in traditional clinical contexts.

Brand names: Tongli
Other names: Bifidobacterium longum subsp. infantis CURE 21婴儿双歧杆菌CURE 21

Beyond the preview

Go deeper on bifidobacterium infantis CURE 21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium infantis CURE 21.

Explore the full profile